A Phase 1/2 interventional study of allo-APZ2-ACLF in Acute-On-Chronic Liver Failure, sponsored by RHEACELL GmbH & Co. KG. Terminated at 5 sites in Germany. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-17.
Sponsored by RHEACELL GmbH & Co. KG · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Acute-On-Chronic Liver Failure with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Acute-On-Chronic Liver Failure · Germany.
Among the 16 studies in Acute-On-Chronic Liver Failure with a site in Germany, this one is one of 2 that started in 2019, is the only one in phase 1/2, and was the 6th registered.
167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.
Browse Acute-On-Chronic Liver Failure studies →6 of the 16 studies in Acute-On-Chronic Liver Failure with a site in Germany are open now. Recruiting first, the newest first:
European Foundation for Study of Chronic Liver Failure · Sites in Germany, France, Italy and 2 more countries
Ages 18–80
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
European Foundation for Study of Chronic Liver Failure · Sites in Germany, United States, Argentina and 24 more countries
Ages 18–80
Johann Wolfgang Goethe University Hospital · Sites in Germany
Ages 18+ · Healthy volunteers
University Hospital, Bonn · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1
First in 2016; this study’s year is marked. 2 started in 2019.
This study's enrollment of 5 is below the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.
Median enrollment 51 across the 9 interventional studies, 400 across the 7 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
RHEACELL GmbH & Co. KG is the lead sponsor of 11 studies on the registry; none are open to participants now.
RHEACELL GmbH & Co. KG has 1 study filed under Acute-On-Chronic Liver Failure — fewer than ten, so there is no comparison to draw.
1 of the studies in Acute-On-Chronic Liver Failure with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Acute-On-Chronic Liver Failure with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an interventional, single arm, multicenter, phase I/IIa clinical trial. The study objective is to investigate the efficacy and safety of three i.v. doses of the investigational medicinal product (IMP) allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF). The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.
This is an interventional, phase I/IIa clinical trial to investigate the efficacy (by changes in Model for End-Stage Liver Disease [MELD] score) and safety (by monitoring adverse events) of the IMP in patients with acute-on-chronic liver failure grade 2 and 3. The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.
The clinical trial will be conducted in Germany and will consist of a screening, treatment and efficacy follow-up period, and a safety follow-up period.The total duration is planned to be about 3 years including the follow-up period.
The planned sample size is up to 18 treated patients. 2 x 10e6 cells/kg, each at Day 0, Day 5 (±1) and Day 13 (±1), will be administrated into peripheral vein (arm) by use of a perfusor. allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in HRG-solution. In patients which require dialysis, the IMP application has to be performed at least 3 hours after end of dialysis. This is necessary to ensure that cells and secreted molecules are not cleared from the system by the dialysis.
Patients will be followed up for 24 weeks with clinic visits at Weeks 3, 4, 8, 12, 16, 20 and 24 after IMP application. Further safety follow-ups will be scheduled as home interviews via telephone at Months 15 and 24. If necessary (at the discretion of the investigator), safety follow-ups at Months 15 and 24 can also be carried out as an on-site visit.
The first six patients will be enrolled into the clinical trial consecutively with an interval of 2 weeks between the third IMP-application of the first patient and the enrolment of the second patient, etc. During this period the patient receives all three applications and immediate severe adverse effects (allergic reactions, SIRS) that could occur after treatment would be reported before treatment start of the next patient.
The safety data of these first six patients will be reviewed by the Medical Monitor continuously, if required with assistance of the further members of the DSMB. The safety evaluation of the DSMB will be submitted to the PEI and recruitment can only be continued after approval of an amendment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Application of IMP into peripheral vein (arm) by use of a perfusor.
Biological: allo-APZ2-ACLF
Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
Also known as: Skin-derived ABCB5-positive mesenchymal stem cells
Change of Model for End-Stage Liver Disease (MELD) score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.
Model for End-Stage Liver Disease (MELD) score for assessing the severity of chronic liver disease is measured as absolute change to baseline score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.
Time frame: Week 24, or last available post-baseline measurement of Days 5 (±1) or 13 (±1) or Weeks 3, 4, 8, 12, 16 or 20 if the Week 24 measurement is missing [LOCF].
Assessment of adverse event (AE) occurrence
All AEs occurring during the clinical trial will be registered, documented and evaluated.
Time frame: Between Screening and Month 24
Change of MELD score at Weeks 3, 4, 8, 12, 16 and 20
Model for End-Stage Liver Disease score is measured as absolute change to baseline score.
Time frame: Weeks 3, 4, 8, 12, 16 and 20
Change of Child-Pugh-Score at Weeks 3, 4, 8, 12, 16, 20 and 24
Child-Pugh-Score to assess the prognosis of chronic liver disease and cirrhosis is measured as absolute change to baseline score.
Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24
Change of CLIF-C ACLF score at Weeks 3, 4, 8, 12, 16, 20 and 24
CLIF-C ACLF score to assess the mortality in Acute-on-chronic liver failure patients is measured as absolute change to baseline score.
Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24
Overall survival time until Week 24
Assessment of overall survival time.
Time frame: Between Screening and Week 24
Complications of ACLF (hepatorenal syndrome [HRS], variceal bleeding, ascites, hepatic encephalopathy [HE], spontaneous bacterial peritonitis [SBP])
Assessment, documentation and evaluattion of ACLF related complications (hepatorenal syndrome, variceal bleeding, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis).
Time frame: Between Screening and Week 24
Transient elastography assessment at Weeks 4, 12 and 24
Mapping of the elastic properties and the stiffness of the tissue as assessed by transient elastography imaging
Time frame: Weeks 4, 12 and 24
Infections (proven infection necessitating systemic use of antibiotics)
All infections occurring during the clinical trial will be registered, documented and evaluated.
Time frame: Between Screening and Month 24
Change of levels of C-reactive protein in serum at Weeks 3, 4, 8, 12, 16, 20 and 24
C-reactive protein levels in the serum will be measured.
Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24
Liver Function Test (ALT, AST, AP, Albumin, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24
The following laboratory variables will be measured and evaluated: Albumin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (AP).
Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24
Changes in the profile of 80 different immunomodulatory cytokines at Weeks 3, 4, 8, 12, 16, 20 and 24
Fluorescence based analysis of 80 different immunomodulatory cytokine parameters in the patient's serum samples as assessed by a 80plex Human Cytokine Antibody Array Kit.
Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24
Changes in dialytic treatment until Week 24
For patients with dialysis prior to Screening: Time to first dialysis after first IMP administration and time to last dialysis after first IMP administration until Week 24 will be assessed. For patients with no dialytic treatment prior to Screening the overall diaylsis timespan from first dialysis after first IMP administration until last dialysis will be measured.
Time frame: Between Screening and Week 24
Time to respiratory failure after first IMP administration until Week 24
Timespan to respiratory failure after first IMP administration until Week 24 will be measured.
Time frame: Between Day 0 (after first IMP administration) and Week 24
Duration of the initial hospital stay
Initial hospitalisation time will be evaluated.
Time frame: Between Screening and Week 24
Duration of initial intensive care stay
The duration of initial intensive care stay will be evaluated.
Time frame: Between Screening and Week 24
Optional: Evaluation of liver biopsy (necrosis quantification)
Extent of necrosis will be quantified by the pathologist of the clinical trial center.
Time frame: Between Week 8 and Week 24
Physical examination at Week 24
A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs.
Time frame: Week 24
Vital signs at Week 24: Body temperature
Body temperature will be measured.
Time frame: Week 24
Vital signs at Week 24: Blood pressure
Blood pressure will be measured.
Time frame: Week 24
Vital signs at Week 24: Heart rate
Heart rate will be measured.
Time frame: Week 24
Vital signs at Week 24: Respiratory rate
Respiratory rate will be measured.
Time frame: Week 24
Hematological laboratory parameters at Week 24
The hematological laboratory values for "hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, platelet count" will be measured.
Time frame: Week 24
Clinical chemistry parameters at Week 24
The clinical chemistry values for "sodium, potassium, calcium, urea, creatinine, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma glytamyl transferase, alkaline phosphatase, CRP" will be measured.
Time frame: Week 24
Coagulation parameter "factor V" at Week 24
The coagulation value for "factor V" will be measured.
Time frame: Week 24
Coagulation parameter "INR" at Week 24
The coagulation value for "INR" will be measured.
Time frame: Week 24
Overall survival at Week 24 and at Month 24
Overall survival at Week 24 and at Month 24 will be evaluated.
Time frame: Week 24, Month 24
Plan to share: No
Ran from Mar 2019 to primary completion in Mar 2021, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acute-On-Chronic Liver Failure →
RHEACELL GmbH & Co. KG